Jason Butler
Stock Analyst at JMP Securities
(3.27)
# 1,072
Out of 4,412 analysts
90
Total ratings
38.46%
Success rate
3.99%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIGL Vigil Neuroscience | Reiterates: Market Outperform | $23 | $2.71 | +748.71% | 3 | Apr 19, 2024 | |
| RZLT Rezolute | Reiterates: Market Outperform | $7 | $2.66 | +163.16% | 6 | Apr 19, 2024 | |
| CRMD CorMedix | Reiterates: Market Outperform | $19 | $5.31 | +257.82% | 6 | Apr 9, 2024 | |
| ARGX argenx SE | Reiterates: Market Outperform | $471 | $372.80 | +26.34% | 4 | Mar 22, 2024 | |
| PGEN Precigen | Reiterates: Market Outperform | $14 | $1.41 | +892.91% | 5 | Mar 20, 2024 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $8 → $10 | $4.07 | +145.70% | 3 | Mar 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $44 → $39 | $16.71 | +133.39% | 11 | Mar 12, 2024 | |
| GHRS GH Research | Maintains: Market Outperform | $50 → $39 | $10.51 | +271.08% | 3 | Mar 1, 2024 | |
| HALO Halozyme Therapeutics | Reiterates: Market Outperform | $72 | $38.57 | +86.67% | 7 | Feb 21, 2024 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $81 → $85 | $20.87 | +307.28% | 6 | Feb 16, 2024 | |
| MOR MorphoSys AG | Reiterates: Market Outperform | $17 | $18.04 | -5.76% | 3 | Nov 21, 2023 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $12.88 | +195.03% | 6 | Nov 14, 2023 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $71 | $65.34 | +8.66% | 7 | Oct 9, 2023 | |
| IRWD Ironwood Pharmaceuticals | Initiates: Market Outperform | $22 | $7.82 | +181.33% | 1 | Sep 28, 2023 | |
| ATHA Athira Pharma | Maintains: Outperform | $20 → $19 | $1.92 | +889.58% | 3 | Aug 11, 2023 | |
| TRVN Trevena | Reiterates: Market Outperform | $2 | $0.41 | +393.34% | 2 | May 17, 2023 | |
| SYRS Syros Pharmaceuticals | Maintains: Market Outperform | $16 → $15 | $5.04 | +197.62% | 2 | May 11, 2023 | |
| NERV Minerva Neurosciences | Downgrades: Market Perform | n/a | $2.44 | - | 1 | Oct 17, 2022 | |
| MRNS Marinus Pharmaceuticals | Maintains: Market Outperform | $21 → $22 | $1.41 | +1,465.84% | 1 | Mar 22, 2022 | |
| QNRX Quoin Pharmaceuticals | Initiates: Market Outperform | n/a | $0.63 | - | 1 | Dec 15, 2021 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | n/a | $12.37 | - | 4 | Nov 23, 2021 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | n/a | $0.89 | - | 1 | Nov 10, 2021 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | n/a | $2.73 | - | 1 | Nov 8, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Outperform | n/a | $1.90 | - | 1 | May 5, 2021 | |
| OVID Ovid Therapeutics | Downgrades: Market Perform | n/a | $3.10 | - | 1 | Dec 2, 2020 | |
| ITCI Intra-Cellular Therapies | Upgrades: Market Outperform | n/a | $73.26 | - | 1 | Aug 24, 2017 |
Vigil Neuroscience
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $23
Current: $2.71
Upside: +748.71%
Rezolute
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $2.66
Upside: +163.16%
CorMedix
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $5.31
Upside: +257.82%
argenx SE
Mar 22, 2024
Reiterates: Market Outperform
Price Target: $471
Current: $372.80
Upside: +26.34%
Precigen
Mar 20, 2024
Reiterates: Market Outperform
Price Target: $14
Current: $1.41
Upside: +892.91%
Aquestive Therapeutics
Mar 15, 2024
Maintains: Outperform
Price Target: $8 → $10
Current: $4.07
Upside: +145.70%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $16.71
Upside: +133.39%
GH Research
Mar 1, 2024
Maintains: Market Outperform
Price Target: $50 → $39
Current: $10.51
Upside: +271.08%
Halozyme Therapeutics
Feb 21, 2024
Reiterates: Market Outperform
Price Target: $72
Current: $38.57
Upside: +86.67%
Prothena Corporation
Feb 16, 2024
Maintains: Market Outperform
Price Target: $81 → $85
Current: $20.87
Upside: +307.28%
MorphoSys AG
Nov 21, 2023
Reiterates: Market Outperform
Price Target: $17
Current: $18.04
Upside: -5.76%
Viridian Therapeutics
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $12.88
Upside: +195.03%
Cytokinetics
Oct 9, 2023
Reiterates: Market Outperform
Price Target: $71
Current: $65.34
Upside: +8.66%
Ironwood Pharmaceuticals
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $7.82
Upside: +181.33%
Athira Pharma
Aug 11, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $1.92
Upside: +889.58%
Trevena
May 17, 2023
Reiterates: Market Outperform
Price Target: $2
Current: $0.41
Upside: +393.34%
Syros Pharmaceuticals
May 11, 2023
Maintains: Market Outperform
Price Target: $16 → $15
Current: $5.04
Upside: +197.62%
Minerva Neurosciences
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.44
Upside: -
Marinus Pharmaceuticals
Mar 22, 2022
Maintains: Market Outperform
Price Target: $21 → $22
Current: $1.41
Upside: +1,465.84%
Quoin Pharmaceuticals
Dec 15, 2021
Initiates: Market Outperform
Price Target: n/a
Current: $0.63
Upside: -
Enanta Pharmaceuticals
Nov 23, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $12.37
Upside: -
HOOKIPA Pharma
Nov 10, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $0.89
Upside: -
Arbutus Biopharma
Nov 8, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $2.73
Upside: -
Esperion Therapeutics
May 5, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $1.90
Upside: -
Ovid Therapeutics
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $3.10
Upside: -
Intra-Cellular Therapies
Aug 24, 2017
Upgrades: Market Outperform
Price Target: n/a
Current: $73.26
Upside: -